I agree that this site is using cookies. You can find further informations here.
X
Svedbom, A
131  results:
Search for persons X
?
1

The psoriasis area and severity index is an independent ris..:

Svedbom, A. ; Ståhle, M.
Journal of the European Academy of Dermatology and Venereology.  37 (2023)  9 - p. 1841-1847 , 2023
Link: https://doi.org/10.1111/..
 
?
2

POSA386 Costs of Hospital Care and Productivity Loss Due to..:

Kjellander, C ; Hernlund, E ; Ivergård, M...
Value in Health.  25 (2022)  1 - p. S248 , 2022
Link: https://doi.org/10.1016/..
 
?
3

A micro-costing analysis of post-fracture care pathways: re..:

Talevski, J. ; Sanders, K. M. ; Lal, A....
Osteoporosis International.  33 (2022)  9 - p. 1895-1907 , 2022
Link: https://doi.org/10.1007/..
 
?
4

Mind the gap: Incidence of osteoporosis treatment after an ..:

Malle, O. ; Borgstroem, F. ; Fahrleitner-Pammer, A....
Bone.  142 (2021)  - p. 115071 , 2021
Link: https://doi.org/10.1016/..
 
?
5

Circulating microRNAs in extracellular vesicles as potentia..:

Pasquali, L. ; Svedbom, A. ; Srivastava, A....
Journal of the European Academy of Dermatology and Venereology.  34 (2020)  6 - p. 1248-1256 , 2020
Link: https://doi.org/10.1111/..
 
?
6

PMS67 EXPERIENCE AND PREFERENCE-BASED EQ-5D-3L VALUE SET DE..:

Svedbom, A. ; Borgstrom, F. ; Hernlund, E....
Value in Health.  22 (2019)  - p. S705-S706 , 2019
Link: https://doi.org/10.1016/..
 
?
7

Real‐world comparative effectiveness of adalimumab, etanerc..:

Svedbom, A. ; Ståhle, M.
Journal of the European Academy of Dermatology and Venereology.  34 (2019)  3 - p. 525-532 , 2019
Link: https://doi.org/10.1111/..
 
?
8

Clinical course of multiple sclerosis and labour‐force abse..:

Castelo‐Branco, A. ; Landfeldt, E. ; Svedbom, A....
European Journal of Neurology.  26 (2019)  4 - p. 603-609 , 2019
Link: https://doi.org/10.1111/..
 
?
9

Cost-effectiveness of pharmacological fracture prevention f..:

Svedbom, A. ; Hadji, P. ; Hernlund, E....
Osteoporosis International.  30 (2019)  9 - p. 1745-1754 , 2019
Link: https://doi.org/10.1007/..
 
?
10

Health-related quality of life during the first year after ..:

Guirant, L. ; Carlos, F. ; Curiel, D....
Osteoporosis International.  29 (2018)  5 - p. 1147-1154 , 2018
Link: https://doi.org/10.1007/..
 
?
11

Quality of life for up to 18 months after low-energy hip, v..:

Svedbom, A. ; Borgstöm, F. ; Hernlund, E....
Osteoporosis International.  29 (2017)  3 - p. 557-566 , 2017
Link: https://doi.org/10.1007/..
 
?
12

Persistence and costs with subcutaneous TNF-alpha inhibitor..:

Svedbom, A ; Dalen, Johan ; Black, Christopher.
Patient Preference and Adherence.  11 (2017)  - p. 95-106 , 2017
Link: https://doi.org/10.2147/..
 
?
13

Quality of life, resource use, and costs related to hip fra..:

Jürisson, M. ; Pisarev, H. ; Kanis, J....
Osteoporosis International.  27 (2016)  8 - p. 2555-2566 , 2016
Link: https://doi.org/10.1007/..
 
?
14

Cost-Effectiveness Analysis of Ixekizumab vs. Secukinumab i..:

Johansson, E ; Svedbom, A ; Kumar, G..
Value in Health.  19 (2016)  7 - p. A568 , 2016
Link: https://doi.org/10.1016/..
 
?
15

Accumulated one Year Health Utility Loss After Sustaining A..:

Guirant, L. ; Carlos, F. ; Clark, P....
Value in Health.  18 (2015)  3 - p. A166 , 2015
Link: https://doi.org/10.1016/..
 
1-15